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In the past the majority of patients with advanced stage
head and neck squamous cell carcinoma (HNSCC) were
treated with a combination of surgery and radiotherapy,
often at the expense of functional and cosmetic morbidity,
and thus reduced quality of life. Nowadays, in an attempt
to decrease the morbidity, non-surgical treatments for
advanced HNSCC are increasingly applied with consider-
able complete remission rates. It appeared that new
radiation schemes (accelerated or hyperfractionated) and
combinations of chemotherapy and radiotherapy all
increase remission rates. When starting an organ sparing
non-surgical therapy for functionally inoperable HNSCC
(i.e. too high morbidity of surgical treatment expected),
salvage surgery is held in reserve for residual or recurrent
disease. However, salvage surgery with curative intent is
only possible in about half of such patients. Moreover, the
complication rate of salvage surgery after chemoradiation
is high, with wound healing problems as a well-known
complication. Since non-surgical treatment itself is also
associated with acute and long-term side effects, leading to
compromised quality of life, patients undergoing primary
non-surgical treatment (radiotherapy with or without che-
motherapy) followed by salvage surgery are exposed to
cumulative morbidity of all treatment modalities. Another
important disadvantage of surgery for residual or recurrent
tumour after radiotherapy is the fact that although it may be
indicated postoperative radiotherapy is mostly no longer
possible, limiting the oncological outcome of this
treatment.
Because salvage treatment after (chemo)radiation car-
ries a questionable prognosis but a high incidence of
complications, (chemo)radiation may not be the choice of
treatment in all patients with advanced HNSCC. A reliable
predictor of outcome after chemoradiation is needed to
select patients who are likely to benefit from non-surgical
treatment.
Valuable predictive factors provide information on the
outcome of therapy in an individual patient allowing
avoidance of over- as well as undertreatment. In the present
context, better selection may refrain a substantial number
of patients from futile extensive and toxic treatment
(radiation with or without chemotherapy), decrease the
complication rate of surgical treatment and reserve radio-
therapy for a postoperative setting if indicated.
Conventional prognostic factors for locoregional control
include T-stage, N-stage and tumour site, grade and vol-
ume. The predictive value of molecular biological markers
is currently under investigation. Tumour metabolism is
another potential prognostic factor and can be studied with
positron emission tomography (PET). Up-regulation of
glucose uptake through overexpression of glucose trans-
porters is an early event in malignant transformation.
18Fluoro-2-deoxyglucose (FDG) is the most widely used
PET tracer in oncologic PET studies and can be used to
measure the glucose metabolism in malignant tissues.
Quantification of tracer uptake can be done in several
ways, from pure visual analysis to simple calculations of
uptake level using a Standardized Uptake Value (SUV; ie.
the ratio of measured activity in a static scan obtained e.g.
60 min after FDG injection over the injected dose and
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normalized for volume of distribution, e.g. body weight)
and to the standard PET approach of the more complicated
kinetic analyses providing the metabolic rate of glucose
uptake (in lmol/min/g). There is a good reproducibility of
metabolic measurements in malignant tumours using FDG-
PET [1]. In untreated primary HNSCC a high correlation
was found between kinetic modelling and simple calcula-
tions with SUV [2]. There is ample proof of principle that
quantitative PET measures have clinical value beyond
visual interpretation. This pertains to prognostic (typically
inverse relation between FDG uptake level and outcome)
as well as predictive aspects (response monitoring). How-
ever, meta-analysis of such data is difficult because SUV
proved anything but standardized in clinical practice. SUV
results highly depend on several aspects that need to be
controlled. This has now been recognized and the proce-
dures to achieve standardised results are now in place [3].
Using these guidelines, larger multicentre studies and
meta-analyses are possible to define clinically appropriate,
externally validated thresholds and criteria.
In HNSCC, SUV during treatment appeared to be more
reliable than visual assessment in predicting treatment
outcome [4]. High SUV pretreatment predicts for signifi-
cantly worse outcome [5–7]. FDG uptake, as measured by
SUV, prior to radiotherapy with or without chemotherapy
for stage II-IV HNSCC has a potential value in predicting
local control, with reported local control rates of 86 and
55% for low (Bmedian) and high SUV, respectively [8].
Other studies reported similar effects on survival. There-
fore, some authors concluded that patients with higher
FDG uptake pretreatment should be considered for a more
aggressive treatment approach or modification of (differ-
ent) treatment modalities to acquire sufficient tumour
control [9]. Sofar, in part due to the interinstitute lack of
standardised PET methods, no reproducible numerical
SUV threshold has been found [10]. Currently, no SUV
cut-off value has been established to stratify patients pre-
treatment in prognostically different subgroups. In the
future SUV might be used for individualized treatment
planning. Inokuchi et al [11] found that pretreatment SUV
of nodal disease was one of the strongest predictive factors
and also provided important information for the selection
of patients suitable for planned neck dissection after che-
moradiation. Unfortunately, no correction for lymph node
volume was performed: due to partial volume effects
smaller lymph nodes will always have lower SUV.
Therefore, the predictive value of uncorrected SUV may be
highly depend on (conventional) size criteria.
In this issue of European Archives of Otorhinolaryn-
gology Haerle et al. [12] examined the correlation between
the pretreatment maximal SUV (SUVmax) and conven-
tional prognostic factors. SUVmax appears to correlate
with T-stage, but not with tumour grade and site. These
findings do not preclude SUVmax from being a potential
predictor. Although this would require a larger study, it
may be more important to find prognostic value of SUV-
max within groups of patients with conventional predictive
factors, e.g. T-stage and subsite. Since smaller tumours
suffer relatively more from partial volume effects (under-
estimating true FDG uptake), it might be expected that
early T-stages have lower SUVmax values, as found in
their study. The authors correctly conclude that the role of
primary tumour SUV as a predictor of outcome or survival
remains unclear and further larger studies are needed. Once
the new PET-guidelines [3] have been implemented, this
should become much less of a task than sofar.
Another approach is predicting the outcome in the early
treatment phase, a clinically significant moment when
switching to a surgical treatment is still possible, before the
appearance of side-effects associated with irradiation and
holding sufficient irradiation in reserve for postoperative
adjuvant treatment. Since conventional CT and MRI can
not reliable distinguish between tumour and postradiation
changes, these anatomical imaging techniques are not
useful in this approach. An effective therapy could very
well result in early subclinical alterations in tumour phys-
iology and biochemistry long before changes in tumour
mass become apparent. Tumour metabolism during cyto-
toxic therapy can be studied within PET [13]. Several
studies report on the association of FDG uptake in the early
phase of treatment and final tumour response. In HNSCC,
FDG-PET uptake during radiotherapy (after 47 Gy) cor-
relates with overall survival [4]. It is also shown that in the
early phase of non-surgical treatment (radiotherapy with or
without chemotherapy) FDG-uptake levels lower than the
median value were associated with a significant higher
local control rate compared to higher FDG-uptake: 96%
and 55% (p = 0.002) respectively [2]. Unfortunately, this
analysis did not account for effect-modification or con-
founding by stage
Whether metabolic changes predict clinical response is
an evolving field of interest in oncology. Clinical studies in
several types and sites of cancer report correlations
between decline in tracer uptake and a positive outcome. If
patients with an adenocarcinoma of the oesophageal junc-
tion were classified as metabolic responders when the
metabolic activity (SUV) of the primary tumour on the
FDG-PET 14 days after the start of neoadjuvant chemo-
therapy had decreased by more than 35% in comparison
with the pretreatment FDG-PET, a predictive value for
residual disease of 95% is found [14]. For gastric carci-
noma this figure is 86% [15]. In HNSCC, SUV reduction
predicts outcome after 2 or 3 cycles of chemotherapy [16].
Unfortunately, no cut-off level was established which can
be used for eventual treatment modification. There are no
such clinical studies on (chemo)radiation in HNSCC.
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FDG-uptake might have predictive value before and
early during non-surgical treatment and may be used in
future to individualize treatment planning. For HNSCC,
only small studies without an established cut-off level are
performed. Large multicentrer studies are needed to
determine and validate the cut-off level and value of FDG
uptake in predicting treatment outcome. PET quantification
with SUVs is affected by many technical and physiological
factors. As a result some of the variations in the literature
on SUV-based patient outcomes are explained by differ-
ences in FDG-PET study methods [17]. These differences
concern patient factors (e.g. plasma glucose levels), time
interval between injection and scanning, image recon-
struction technique, image quality and SUV measure used.
Therefore, different studies are difficult to compare and
meta-analysis will not be possible. In designing prospective
multicenter studies to examine the value of SUV in the
prediction of treatment outcome, calibration of PET-scan-
ners and standardisation of PET-scanning protocols should
be performed. Guidelines for standardisation and quantifi-
cation of FDG uptake have been developed. A great
challenge in the near future will be to implement and
maintain standards in large multicenter trials [3]. Multi-
center studies including large series of homogenous groups
of patients with standardized FDG-PET scanning and
quantification protocols are needed to determine the opti-
mal cut-off level and clinical value of SUV in treatment
planning of HNSCC patients.
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